Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Glaxosmithkline Biologicals S a patents


Recent patent applications related to Glaxosmithkline Biologicals S a. Glaxosmithkline Biologicals S a is listed as an Agent/Assignee. Note: Glaxosmithkline Biologicals S a may have other listings under different names/spellings. We're not affiliated with Glaxosmithkline Biologicals S a, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxosmithkline Biologicals S a-related inventors


Immunogenic composition

present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.... Glaxosmithkline Biologicals S a

Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins

The present invention relates to immunogenic compositions comprising isolated Clostridium difficile CDTb and/or CDTa protein. In particular the isolated Clostridium difficile CDTb protein is suitably a truncated CDTb protein comprising the receptor binding domain or a mutated CDTb protein incapable of binding to CDTa, and the isolated Clostridium difficile CDTa... Glaxosmithkline Biologicals S a

Cmv antigens and uses thereof

The invention relates to a recombinant human cytomegalovirus (CMV) protein dimeric complex comprising CMV gH protein or a complex-forming fragment thereof, and CMV UL116 or a complex-forming fragment thereof. Also provided herein are nucleic acids encoding said gH/UL116 dimeric complex, host cells for recombinant expression of said gH/UL116 dimeric complex,... Glaxosmithkline Biologicals S a

Vaccination

The present invention relates to compositions for use in and methods for protecting against Herpes Zoster (HZ).... Glaxosmithkline Biologicals S a

Mammalian cells expressing cytomegalovirus antigens

This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.... Glaxosmithkline Biologicals S a

Nucleotide sequences, vectors and host cells

The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of Clostridium difficile, wherein the polypeptide elicits antibodies that neutralize toxin A or toxin B or both.... Glaxosmithkline Biologicals S a

Immunogenic composition

The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminium-free adjuvant.... Glaxosmithkline Biologicals S a

Complexes of cytomegalovirus proteins

An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying... Glaxosmithkline Biologicals S a

Vaccine

The present invention relates to Human Rhinovirus (HRV) Virus-Like Particles (VLPs) and methods of making HRV VLPs.... Glaxosmithkline Biologicals S a

Ultrafiltration for preparing outer membrane vesicles

In place of a step of centrifugation during preparation of outer membrane vesicles (OMVs) from bacteria, the invention utilises ultrafiltration. This allows much larger amounts of OMV-containing supernatant to be processed in a much shorter time. Thus the invention provides a process for preparing bacterial OMVs, comprising a step of... Glaxosmithkline Biologicals S a

Nucleotide sequences, vectors and host cells

Polynucleotides encoding fusion proteins comprising fragments of toxin A and toxin B from Clostridium difficile are described, as well as vectors and host cells containing such polynucleotides.... Glaxosmithkline Biologicals S a

Immunogenic composition

The present disclosure relates to the field of Neisserial immunogenic compositions and vaccines, their manufacture and the use of such compositions in medicine. In particular the present invention relates to compositions and methods involving the factor H binding protein (fHbp) antigen. The present inventors have recognised that fHbp is poorly... Glaxosmithkline Biologicals S a

Novel method and compositions

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides... Glaxosmithkline Biologicals S a

Saccharide vaccine formulation

Substantially stable vaccine compositions are provided, as are methods for their use and manufacture.... Glaxosmithkline Biologicals S a

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an M72 related antigen and wherein a subsequent administration is delayed.... Glaxosmithkline Biologicals S a

Vaccine

Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.... Glaxosmithkline Biologicals S a

Method for inducing a trif-bias

Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF-biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.... Glaxosmithkline Biologicals S a

Novel compositions and methods

The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment... Glaxosmithkline Biologicals S a

Immunogenic composition

The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are... Glaxosmithkline Biologicals S a

Vaccine compositions comprising a saponin adjuvant

The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said... Glaxosmithkline Biologicals S a

Immunogenic composition for use in therapy

This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.... Glaxosmithkline Biologicals S a

Expression systems

The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an... Glaxosmithkline Biologicals S a

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.... Glaxosmithkline Biologicals S a








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Biologicals S a in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Biologicals S a with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###